IL320004A - שיטות לטיפול בהפרעות בתיווך קולטן אסטרוגן - Google Patents

שיטות לטיפול בהפרעות בתיווך קולטן אסטרוגן

Info

Publication number
IL320004A
IL320004A IL320004A IL32000425A IL320004A IL 320004 A IL320004 A IL 320004A IL 320004 A IL320004 A IL 320004A IL 32000425 A IL32000425 A IL 32000425A IL 320004 A IL320004 A IL 320004A
Authority
IL
Israel
Prior art keywords
compound
kit
pharmaceutically acceptable
acceptable salt
cancer
Prior art date
Application number
IL320004A
Other languages
English (en)
Inventor
Pamela M Klein
Original Assignee
Olema Pharmaceuticals Inc
Novartis Ag
Pamela M Klein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olema Pharmaceuticals Inc, Novartis Ag, Pamela M Klein filed Critical Olema Pharmaceuticals Inc
Publication of IL320004A publication Critical patent/IL320004A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL320004A 2022-10-05 2023-10-04 שיטות לטיפול בהפרעות בתיווך קולטן אסטרוגן IL320004A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263413475P 2022-10-05 2022-10-05
PCT/US2023/034454 WO2024076626A1 (en) 2022-10-05 2023-10-04 Methods of treating estrogen receptor-mediated disorders

Publications (1)

Publication Number Publication Date
IL320004A true IL320004A (he) 2025-06-01

Family

ID=90608897

Family Applications (1)

Application Number Title Priority Date Filing Date
IL320004A IL320004A (he) 2022-10-05 2023-10-04 שיטות לטיפול בהפרעות בתיווך קולטן אסטרוגן

Country Status (8)

Country Link
EP (1) EP4598520A1 (he)
JP (1) JP2025533900A (he)
KR (1) KR20250095627A (he)
CN (1) CN120187424A (he)
AU (1) AU2023356291A1 (he)
IL (1) IL320004A (he)
MX (1) MX2025004050A (he)
WO (1) WO2024076626A1 (he)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120157402A1 (en) * 2009-05-27 2012-06-21 Liangxian Cao Methods for treating brain tumors
MX373926B (es) * 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
KR102710603B1 (ko) * 2015-10-01 2024-09-27 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
CA3109090A1 (en) * 2018-08-17 2020-02-20 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for the treatment of breast cancer
CN115175679A (zh) * 2020-03-06 2022-10-11 奥列马制药公司 治疗雌激素受体相关疾病的方法

Also Published As

Publication number Publication date
CN120187424A (zh) 2025-06-20
MX2025004050A (es) 2025-05-02
WO2024076626A1 (en) 2024-04-11
KR20250095627A (ko) 2025-06-26
EP4598520A1 (en) 2025-08-13
AU2023356291A1 (en) 2025-04-17
JP2025533900A (ja) 2025-10-09

Similar Documents

Publication Publication Date Title
US10765684B2 (en) Reduction of side effects from aromatase inhibitors used for treating breast cancer
US8853188B2 (en) Compositions and methods for cancer treatment
IL314360B2 (he) שיטה לסינתזת אנלוגים להורמון בלוטת התריס ופולימורפים שלהם
IL320452A (he) טיפול משולב עבור סרטן הערמונית
US20160113925A1 (en) Methods of treating cancer with a combination of glucose modulators and bcl-2 inhibitors
US20110190244A1 (en) Method of treatment of egfr inhibitor toxicity
CN109562080A (zh) 用于治疗癌症和癌症并发症的药物组合物
CN110049866A (zh) 多金属氧酸盐络合物及其在癌症治疗中的应用
CN102441168B (zh) 含芹菜素及芹菜素类衍生物和Bcl-2抑制剂的药物组合物及其在制备治疗癌症的药物中的应用
JP2012527424A5 (he)
IL320004A (he) שיטות לטיפול בהפרעות בתיווך קולטן אסטרוגן
JP5289310B2 (ja) 微小管破壊剤及びそれを含有する癌細胞増殖抑制剤
CN101836989B (zh) 含有粉防己碱及粉防己碱类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
Guo et al. Estrogen Receptor α (ERα)-targeting compounds and derivatives: Recent advances in structural modification and bioactivity
RU2025111136A (ru) Способы лечения опосредованных рецептором эстрогена нарушений
CN113507932B (zh) 3-o-氨基磺酸-16,16-二甲基-d-高马萘雌甾酮在治疗肿瘤疾病中的用途
EP4085911A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION FOR THE TREATMENT OF LIVER CANCER
MXPA04005771A (es) Composicion de estrogeno y de otras hormonas con ascorbato, lisina, prolina y otras substancias.
CN103751184B (zh) 孕烷x受体拮抗剂在制备调脂与保肝产品中的应用
US20240366562A1 (en) Gynecomastia and/or mastalgia treatment
TW200902028A (en) Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in BRCA mediated diseases
US20160095859A1 (en) Combination therapies for overcoming resistance to mitotic agents during chemotherapy
HK40110445A (zh) 男性乳房发育症和/或乳腺痛治疗
AU2012200290B2 (en) Reduction of side effects from aromatase inhibitors used for treating breast cancer
AU2006303878B2 (en) Reduction of side effects from aromatase inhibitors used for treating breast cancer